BioRestorative to Present a BRTX-100 Clinical Update at ISCT 2025

About BRTX-100 BRTX-100, a novel cell-based therapeutic engineered to target areas of the body that have little blood flow, is BioRestorative's lead clinical candidate. The safety and efficacy of BRTX-100 in treating chronic lumbar disc disease ("cLDD") is being evaluated in a Phase 2, prospective, randomized, double-blinded and controlled study. The U.S. Food and Drug Administration ("FDA") recently granted Fast Track designation to the BRTX- 100 program for the treatment of cLDD, reflecting the positive p ...